Depomed, Inc. (NYSE:ASRT) Director Arthur J. Higgins bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $77,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
NYSE:ASRT remained flat at $$1.52 during trading hours on Monday. 2,119,204 shares of the company traded hands, compared to its average volume of 843,380. Depomed, Inc. has a twelve month low of $1.49 and a twelve month high of $8.08. The company has a 50 day moving average of $3.04.
Several brokerages recently commented on ASRT. Mizuho decreased their target price on shares of Depomed from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, May 16th. Zacks Investment Research cut shares of Depomed from a “buy” rating to a “hold” rating in a report on Monday, July 29th.
Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Read More: What is meant by holder of record?
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.